Medicare Enrolled
Dr. Juan Iribarren, MD
Pulmonary Disease · Beaumont, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Iribarren from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Iribarren?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Iribarren
Dr. Juan Iribarren is a pulmonary disease specialist in Beaumont, TX, with 18 years of NPI registration. Based on federal Medicare data, Dr. Iribarren performed 5,334 Medicare services across 1,815 unique beneficiaries.
Between the years covered by Open Payments, Dr. Iribarren received a total of $693,064 from 38 pharmaceutical and/or device companies across 898 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Iribarren is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 3% volume in TX
$693,064 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,334
Medicare services
Top 3% in TX for pulmonary disease
1,815
Unique beneficiaries
$31
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~296 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Allergy skin test A diagnostic test performed to identify specific allergies by applying or introducing allergenic extracts to the body. The procedure measures the patient's immune response to various potential allergens. |
1,402 | $3 | $9 |
| Allergy immunotherapy preparation A professional service involving the preparation and administration of one or more antigens. |
975 | $11 | $29 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
633 | $61 | $152 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
380 | $91 | $238 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
220 | $39 | $94 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
208 | $0 | $10 |
| Chest X-ray, 2 views An X-ray imaging test of the chest that captures two different angles to visualize the lungs, heart, and chest wall. |
151 | $16 | $79 |
| Allergy injection therapy, multiple injections A professional service involving the administration of multiple allergen injections. |
136 | $8 | $23 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
135 | $101 | $250 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
110 | $135 | $334 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
105 | $0 | $10 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
101 | $39 | $110 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
100 | $41 | $113 |
| Skin allergy test A test where small amounts of potential allergens are injected into the skin to check for allergic reactions. |
94 | $5 | $16 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
88 | $20 | $60 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
79 | $9 | $36 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
78 | $93 | $226 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
66 | $24 | $65 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
59 | $123 | $319 |
| Hospital discharge day management, 30 minutes or less This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less. |
56 | $63 | $146 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
49 | $12 | $33 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
32 | $60 | $158 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
24 | $64 | $160 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
22 | $68 | $204 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
16 | $27 | $94 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
15 | $7 | $10 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$693,064
Total received (2018-2024)
Avg $99,009/year across 7 years
Top 1% in TX for pulmonary disease
38
Companies
898
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$684,532 (98.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,272 (1.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,260 (0.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$259,636
2023
$77,574
2022
$81,685
2021
$71,457
2020
$111,946
2019
$89,341
2018
$1,425
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$369,261
GENZYME CORPORATION
$224,910
AstraZeneca Pharmaceuticals LP
$69,410
Regeneron Healthcare Solutions, Inc.
$22,314
ViiV Healthcare Company
$1,600
Actelion Pharmaceuticals US, Inc.
$1,005
Boehringer Ingelheim Pharmaceuticals, Inc.
$897
Boston Scientific Corporation
$551
Insmed, Inc.
$463
PFIZER INC.
$452
Philips Electronics North America Corporation
$356
BOSTON SCIENTIFIC CORPORATION
$276
Mylan Specialty L.P.
$235
Gilead Sciences, Inc.
$230
United Therapeutics Corporation
$121
Sunovion Pharmaceuticals Inc.
$90
Janssen Pharmaceuticals, Inc
$88
Amgen Inc.
$87
Merck Sharp & Dohme Corporation
$85
Electromed, Inc.
$82
Ethicon US, LLC
$79
SANOFI-AVENTIS U.S. LLC
$58
Circassia Pharmaceuticals Inc
$51
Novartis Pharmaceuticals Corporation
$47
Inspire Medical Systems, Inc.
$45
Takeda Pharmaceuticals U.S.A., Inc.
$43
ABBVIE INC.
$42
INOGEN, INC.
$23
Melinta Therapeutics, LLC
$20
Vapotherm Inc
$18
Allergan Inc.
$18
Bayer HealthCare Pharmaceuticals Inc.
$17
E.R. Squibb & Sons, L.L.C.
$17
Nuwellis, Inc.
$17
Merck Sharp & Dohme LLC
$16
Pulmonx Corporation
$16
Inogen, Inc.
$13
Shire North American Group Inc
$11
Top 3 companies account for 95.7% of total payments
Associated products mentioned in payments ›
(8874) inCourage · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Acquire · Adempas · Aquadex Smartflow Console · Arikayce · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BROVANA · Baxdela · CHANTIX · CHARTIS CATHETER · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · ELIQUIS · FARXIGA · FASENRA · GENERAL - THERAPIES · GLASSIA · IMFINZI · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · INSPIRE · InogenOne · LATITUDE · LINX Reflux Management System · LONHALA MAGNAIR · LUX DX · LUX-DX · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · Perforomist · RESONATE · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA RESPIMAT · SQ-RX PULSE GENERATOR · STIOLTO RESPIMAT · SYMBICORT · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · Trilogy 100 · UPTRAVI · UTIBRON · Utibron · VAPOTHERM · Veklury · Wellcentive Undiv · XARELTO · XOLAIR · Yupelri · ZERBAXA · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (99%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for pulmonary disease in TX.
Equivalent to $12,993 per 100 Medicare services performed
Geographic Context
Pulmonary diseases within 10 mi
4
Per 100K population
1.6
County median income
$59,934
Nearest hospital
BAPTIST BEAUMONT HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Iribarren is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), with speaking/promotional industry engagement in the top 1% of TX peers, with 18 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Iribarren experienced with allergy skin test?
Based on Medicare claims data, Dr. Iribarren performed 1,402 allergy skin test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Iribarren receive payments from pharmaceutical companies?
Yes. Dr. Iribarren received a total of $693,064 from 38 companies across 898 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Iribarren's costs compare to other pulmonary diseases in Beaumont?
Dr. Iribarren's average Medicare payment per service is $31. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Iribarren) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Beaumont
Browse pulmonary diseases in Beaumont ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in TX
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in TX
Which TX pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology